Earnings summaries and quarterly performance for Corteva.
Executive leadership at Corteva.
Charles V. Magro
Detailed
Chief Executive Officer
CEO
DP
David P. Johnson
Detailed
Executive Vice President, Chief Financial Officer
JA
Jennifer A. Johnson
Detailed
Senior Vice President, Chief Legal Officer
RD
Robert D. King
Detailed
Executive Vice President, Crop Protection Business Unit
SR
Samuel R. Eathington
Detailed
Executive Vice President, Chief Technology & Digital Officer
Board of directors at Corteva.
DC
David C. Everitt
Detailed
Director
GR
Gregory R. Page
Detailed
Chair of the Board
JP
Janet P. Giesselman
Detailed
Director
KH
Karen H. Grimes
Detailed
Director
KJ
Kerry J. Preete
Detailed
Director
KA
Klaus A. Engel
Detailed
Director
LA
Lamberto Andreotti
Detailed
Director
MM
Marcos M. Lutz
Detailed
Director
MO
Michael O. Johanns
Detailed
Director
NR
Nayaki R. Nayyar
Detailed
Director
PJ
Patrick J. Ward
Detailed
Director
Research analysts who have asked questions during Corteva earnings calls.
ER
Edlain Rodriguez
Mizuho Securities
6 questions for CTVA
Also covers: ALB, BALL, CCK +6 more
Joel Jackson
BMO Capital Markets
6 questions for CTVA
Also covers: AGCO, ALB, ALTM +11 more
Kevin McCarthy
Vertical Research Partners
6 questions for CTVA
Also covers: ALB, ALTM, APD +17 more
Vincent Andrews
Morgan Stanley
6 questions for CTVA
Also covers: ALB, APD, AVNT +20 more
DB
David Begleiter
Deutsche Bank
5 questions for CTVA
Also covers: ALB, APD, ASH +24 more
Patrick Cunningham
Citigroup
5 questions for CTVA
Also covers: ALB, APD, AXTA +17 more
CP
Christopher Parkinson
Wolfe Research
4 questions for CTVA
Also covers: ALB, APD, ASH +17 more
JZ
Jeffrey Zekauskas
JPMorgan Chase & Co.
4 questions for CTVA
Also covers: ALB, APD, ASH +30 more
Kristen Owen
Oppenheimer & Co. Inc.
4 questions for CTVA
Also covers: , AGCO, AVNT +15 more
Frank Mitsch
Fermium Research
3 questions for CTVA
Also covers: AVNT, CE, DD +13 more
Joshua Spector
UBS
3 questions for CTVA
Also covers: ALB, AMBP, APD +37 more
Matthew Deyoe
Bank of America
3 questions for CTVA
Also covers: APD, AXTA, CF +12 more
AV
Aaron Viswanathan
RBC Capital Markets
2 questions for CTVA
Also covers: AMCR
AV
Aleksey V. Yefremov
KeyBanc Capital Markets Inc.
2 questions for CTVA
Also covers: RPM
AY
Aleksey Yefremov
KeyBanc Capital Markets
2 questions for CTVA
Also covers: ALB, ALTM, AXTA +14 more
AV
Arun Viswanathan
RBC Capital Markets
2 questions for CTVA
Also covers: ALB, AMBP, AMCR +25 more
BT
Ben Thayer
Barclays
2 questions for CTVA
CP
Chris Parkinson
Wolfe Research, LLC
2 questions for CTVA
Also covers: AXTA, CCK, DD +6 more
DR
Dan Rizwan
Jefferies
2 questions for CTVA
Duffy Fischer
Goldman Sachs
2 questions for CTVA
Also covers: APD, AXTA, CC +9 more
JS
Josh Spector
UBS Group
2 questions for CTVA
Also covers: ALB, AMBP, APD +27 more
Richard Garchitorena
Wells Fargo
2 questions for CTVA
Also covers: CF, DOW, FMC +2 more
Steve Byrne
Bank of America
2 questions for CTVA
Also covers: ADM, APD, AXTA +19 more
Emily Fusco
Deutsche Bank
1 question for CTVA
Also covers: APD, CBT, FUL +3 more
PF
Patrick Fischer
Goldman Sachs
1 question for CTVA
Also covers: APD, AXTA, CC +8 more
Rachel Leon
Citigroup Inc.
1 question for CTVA
SL
Salvo Latiano
Bank of America
1 question for CTVA
Recent press releases and 8-K filings for CTVA.
Corteva reports Q4 and full-year 2025 results
CTVA
Earnings
Guidance Update
Legal Proceedings
- Q4 2025 GAAP net sales were $3.91 B with a GAAP loss from continuing operations of $537 M (EPS $(0.80)); non-GAAP organic sales were $3.82 B, operating EBITDA $446 M, and operating EPS $0.22.
- FY 2025 net sales rose 3% to $17.40 B, GAAP EPS was $1.75, and non-GAAP operating EBITDA reached $3.85 B (operating EPS $3.34).
- Generated $3.5 B in operating cash flow (+51%) and $2.9 B in free cash flow (+69%), supporting over $1.5 B returned to shareholders in 2025.
- Full-year 2026 guidance calls for operating EBITDA of $4.0–$4.2 B and operating EPS of $3.45–$3.70.
- Reached comprehensive litigation resolution with Bayer to accelerate licensing and freedom to operate, with a $610 M cash outflow expected in Q1 2026.
11 hours ago
Corteva reports Q4 2025 earnings results
CTVA
Earnings
Guidance Update
- Net sales of $3.91 billion in Q4 2025, down 2% year-over-year; GAAP Operating EBITDA was $446 million (–15%), with margin at 11.4% (–179 bps).
- Seed net sales of $1.74 billion (–2%), with Seed Operating EBITDA up 33% to $124 million; Crop Protection Operating EBITDA declined to $360 million from $461 million in Q4 2024.
- Q4 Operating EPS of $0.22 (–31%) versus $0.32 in Q4 2024; GAAP EPS loss of $0.80 per share versus a loss of $0.08.
- Full-year Operating EPS of $3.34 (up from $2.57 in FY 2024), driven by volume/price gains and cost savings; FY 2026 guidance calls for low-to-mid single-digit revenue growth and $4.0–$4.2 billion of Operating EBITDA.
12 hours ago
Corteva reports Q4 and full-year 2025 results
CTVA
Earnings
Guidance Update
- Q4 2025 results included net sales of $3.91 B, a GAAP loss per share of $(0.80), and non-GAAP EPS of $0.22
- Full-year 2025 net sales were $17.40 B (up 3% vs. 2024); non-GAAP Operating EBITDA was $3.85 B and Operating EPS was $3.34
- Cash provided by operations was $3.5 B (+51%) with free cash flow of $2.9 B (+69%), supporting over $1.5 B returned to shareholders
- 2026 guidance calls for Operating EBITDA of $4.0–4.2 B and Operating EPS of $3.45–3.70 per share
- The company remains on track to complete its planned separation in the second half of 2026
12 hours ago
Corteva and bp launch Etlas biofuel feedstock JV
CTVA
New Projects/Investments
Management Change
- Corteva and bp have formed a 50:50 joint venture, Etlas, to produce oil from canola, mustard and sunflower crops as feedstock for sustainable aviation fuel (SAF) and renewable diesel (RD).
- Etlas targets 1 million metric tonnes of feedstock per year by the mid-2030s (enough to yield over 800,000 tonnes of biofuel) and plans to begin initial supply in 2027.
- The venture will source intermediate crops grown on existing cropland between main food seasons, enhancing soil health and providing farmers with new revenue streams.
- Ignacio Conti will serve as CEO and Gaurav Sonar as Chair of the Board of Directors for Etlas.
Jan 7, 2026, 11:00 AM
Corteva forms JV with Hexagon Bio for nature-inspired crop protection
CTVA
New Projects/Investments
- Corteva and Hexagon Bio launched a multi-million-dollar joint venture to accelerate development of nature-inspired crop protection solutions.
- The JV merges Corteva’s billion-dollar nature-inspired crop protection franchises and bacterial natural product discovery capabilities with Hexagon Bio’s natural-product discovery platform.
- It is the first agriculture-sector JV for Hexagon Bio and the first pharmaceutical JV for Corteva, targeting cross-industry pipeline advancement.
- The JV is facilitated through Corteva Catalyst, which has partnered with 11 companies since its March 2024 launch.
Dec 16, 2025, 1:00 PM
Corteva reports Q3 2025 earnings
CTVA
Earnings
Guidance Update
- Q3 2025 net sales were $2.6 B, up 13% YoY, and organic sales grew 11% on strong seed and crop protection volumes.
- Q3 Operating EBITDA turned positive at $49 M vs. a $(100) M loss a year ago, with operating margin expanding to 1.9% from –4.3% (+617 bps).
- YTD net sales reached $13.5 B (+4%), organic sales were +6%, and YTD Operating EBITDA was $3.4 B (+19%) with a 25.2% margin (+317 bps); Corteva raised FY 2025 Operating EBITDA guidance to $3.80–$3.90 B (+14% at midpoint).
- On track to complete the separation into two public companies—New Corteva and SpinCo—in 2H 2026, creating focused platforms in crop protection, plant health, and advanced genetics.
Nov 5, 2025, 2:00 PM
Corteva announces Q3 2025 results
CTVA
Earnings
Guidance Update
Product Launch
- Intent to separate Corteva into two public companies (seed and crop protection) by second half 2026 to unlock growth potential in each segment.
- Q3 organic sales rose 11% and volumes 12% year-over-year; year-to-date operating EBITDA reached $3.4 billion (+19%) with a margin above 25% (+320 bps).
- Full-year operating EBITDA guidance raised to $3.8 billion–$3.9 billion (midpoint +14% YoY), with over $600 million in controllable benefits now expected for 2025.
- Product launch: unveiled Varpalgo, a next-generation insecticide targeting chewing pests, expected in the early 2030s and forecasted to peak at $750 million in revenue.
Nov 5, 2025, 2:00 PM
Corteva announces Q3 2025 results and separation plans
CTVA
Earnings
Guidance Update
M&A
- Corteva confirmed its intent to separate into two public companies—seed and crop protection—with a targeted second-half 2026 separation and a global CEO search underway to lead the new Corteva entity .
- In Q3 2025, organic sales grew 11% and volumes rose 12%, driving positive operating EBITDA versus a prior-year loss and about 600 bps of margin expansion; year-to-date organic sales climbed 6%, operating EBITDA reached $3.4 billion (up 19%), and margin exceeded 25% (up 320 bps) .
- Full-year 2025 guidance was raised to $3.8 billion–$3.9 billion of operating EBITDA (14% growth at midpoint), $3.25–$3.35 of operating EPS (28% growth at midpoint), free cash flow of ~$1.9 billion (50% conversion), and $1 billion of share repurchases .
- Looking to 2026, Corteva anticipates $4.1 billion of operating EBITDA (mid-single-digit growth) and expects low single-digit growth in the crop protection industry (with high single-digit growth in biologicals) .
Nov 5, 2025, 2:00 PM
Corteva announces Q3 2025 results and separation plan
CTVA
Earnings
Guidance Update
Share Buyback
- On October 1, Corteva announced intent to separate into two public companies, targeting a second-half 2026 separation and initiating a global CEO search for the new seed entity.
- Q3 organic sales rose 11%, volumes grew 12%, and operating EBITDA turned positive with over 600 bps of margin expansion versus a loss in the prior year.
- Raised full-year 2025 operating EBITDA guidance to $3.8 billion–$3.9 billion (14% growth at midpoint) and increased operating EPS outlook to $3.25–$3.35, while reconfirming ~50% free cash flow conversion.
- Committed to $1 billion in share repurchases and a total cash return of $1.5 billion (including dividends) for 2025.
Nov 5, 2025, 2:00 PM
Corteva reports Q3 2025 results and raises full-year guidance
CTVA
Earnings
Guidance Update
- Corteva delivered Q3 net sales of $2.62 B, GAAP loss from continuing operations of $(308) M (EPS $(0.46)), and non-GAAP operating EBITDA of $49 M (operating EPS $(0.23)).
- Nine-month 2025 net sales reached $13.49 B (+4% vs. 2024), GAAP income from continuing operations was $1.74 B (EPS $2.54), and non-GAAP operating EBITDA was $3.40 B (operating EPS $3.11).
- Full-year 2025 guidance was raised: net sales of $17.7 B–$17.9 B, operating EBITDA of $3.8 B–$3.9 B, and operating EPS of $3.25–$3.35; 2026 operating EBITDA preliminarily expected at $4.1 B.
- The company reaffirmed its planned separation into two public entities (“New Corteva” for crop protection and “SpinCo” for seed and biotech) in H2 2026 to optimize capital allocation and focus.
Nov 4, 2025, 9:40 PM
Quarterly earnings call transcripts for Corteva.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more